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Long-Lasting Complete
Remission with
Tyrosine Kinase
Inhibitor in
Bronchioloalveolar
Carcinoma with a so
far Unknown EGFR
Mutation
To the Editor:
The epidermal growth factor recep-
tor (EGFR) has been validated in several
preclinical studies as an important target
for novel molecular targeted therapy for
human carcinomas. Strategies to inhibit
EGFR include the use of blocking anti-
bodies and small-molecule tyrosine kinase
inhibitors. Gefitinib was approved in the
USA by the US Food and Drug Adminis-
tration in May 2003 for the treatment of
advanced non-small cell lung cancer
(NSCLC) in patients previously treated
with chemotherapy. However, a large
phase III randomized clinical trial did not
find a significant benefit from gefitinib,
when compared with placebo,1 whereas
other reports have described an associa-
tion between clinical response to gefitinib
and activating mutations of the EGFR ki-
nase domain.2,3
Han et al.4 performed an analysis
of EGFR mutation in a large series of
NSCLC cases reporting EGFR muta-
tions in 10% of the 375 adenocarcino-
mas, but none in the 454 squamous-cell
carcinomas examined; 26% of 86 bron-
chioloalveolar carcinomas (BAC) and
6% of 289 conventional adenocarcino-
mas harbored EGFR mutations. Two in-
dependent groups have provided evi-
dence of significantly increased survival
of NSCLC patients with mutated EGFR
in response to gefitinib.5,6
Here, we report the case of a 48-
year-old man, nonsmoker with meta-
static BAC of the lung that responded to
gefitinib. BAC of the right lung was
diagnosed in May 2003. After radical
pneumonectomy and hilar and mediasti-
num nodes excision (pT4N2M0), the pa-
tient was treated with four courses of
adjuvant chemotherapy with cisplatin-
gemcitabine.
One year later, the patient devel-
oped cough, bronchorrea, and dyspnea.
A total body computed tomography
(CT) scan showed a contralateral diffuse
relapse of disease, with ground glass
lesions in the entire left lung. Sputum
cytology confirmed BAC cells. The pa-
tient was treated with two courses of
cisplatin-gemcitabine. In May 2005, he
presented a serious dyspnea requiring per-
manent O2-delivery and a CT of the chest
showed disease progression (Figure 1A).
ECOG performance status was 4. On the
basis of the histologic diagnosis, non-
smoker, chemotherapy-refractory disease,
we decided to start treatment with gefitinib
(Iressa, Astra Zeneca, Pharmaceuticals,
Wilmington, DE) 250 mg/os/daily. The
patient’s respiratory status and general
condition improved over a few days, and a
CT scan showed a partial remission with
minimal residual disease and ground glass
areas still scattered in the pulmonary pa-
renchyma. In September 2006, a new CT
scan (Figure 1B) demonstrated a complete
remission, which is still long-lasting. In
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FIGURE 1. (A) Computed tomography (CT) chest scan at relapse of disease (May
2005); (B) CT chest scan after gefitinib therapy (September 2006); (C) Sequencing
of exon 20 shows two heterozygous mutations in tumor tissue DNA: a C to Y (C
or T) base-pair change (red arrow), resulting in a substitution of phenylalanine for
serine at position 784 (S784F); a G to R (A or G) base-pair change (black arrow),
resulting in a substitution of methionine for valine at position 786 (V786M); (D)
Sequencing of exon 20, derived from tumor tissue DNA, cloned fragment in plas-
mid: single mutation in homozygous shows a C to T base-pair change, resulting in
a substitution of phenylalanine for serine at position 784 (S784F), (E) Single muta-
tion in homozygous shows a G to A base-pair change, resulting in a substitution of
methionine for valine at position 786 (V786M).
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December 2007, the patient is still on
treatment with gefitinib and he is enjoying
an absolutely normal quality of life.
Molecular analyses of the tumor
specimen that was collected from the
primary tumor resected showed the fol-
lowing: the immunohistochemistry of
EGFR protein was negative and phospho-
Akt status was positive in more than 70%
of tumor cells; fluorescence in situ hybrid-
ization of EGFR and HER2 genes copy
number showed no amplification.
DNA sequencing performed on
the same tissue analyzed by immunohis-
tochemistry and fluorescence in situ hy-
bridization detected two heterozygous
mutations on EGFR exon 20, (S784F)
and (V786M) (Figure 1C). This se-
quence mutation was confirmed from
both directions in three independent
PCR experiments from three original
DNA extractions. The mutation S784F
had been previously reported by Tsao
et al.,7 whereas the V786M mutation is
today a novel variant mutation. To as-
sess if the presence of the mutations
located in exon 20 of EGFR was in the
same allele or was placed as single mu-
tation in both alleles of the patient, we
amplified by PCR and cloned the exon
20 in bacterial plasmid. The sequence of
the exon 20 inserted in the plasmids
showed a single mutation for individual
plasmid (Figures 1D, E). These data
indicate that in both alleles the EGFR
gene is mutated and the patient shows
heterozygous for each single mutation.
No mutation was found in peripheral
white blood cells indicating the somatic
origin of these mutations in the tumor. No
information on functional significance of
observed mutations is available, and none
of these mutations have been reported as
polymorphisms. Conversely, no mutation
on exon 2 (12 and 13 codons) of KRAS
gene was demonstrated.
We demonstrate that two genetic
mutations in exon 20 of the EGFR gene
affect both alleles in heterozygous and
we reveal a novel variant mutation at
position 786 (V786M). We suggest that
the two simultaneous mutations in het-
erozygous may be associated with an
EGFR-dependent molecular tumor phe-
notype of NSCLC. These mutations may
be responsible for the unusually com-
plete and lasting response to the EGFR-
inhibitor gefitinib in this patient. We
consider that this report could be partic-
ularly relevant because until now the
EGFR exon 20 mutation has been asso-
ciated with intrinsic resistance to ty-
rosine kinase inhibitors.8
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